Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naporafenib combinations in advanced NSCLC or melanoma
NCT02974725Phase 1Terminated
- Sponsor
- Novartis
- Start
- Feb 2017
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 1, open-label trial of naporafenib in non-small cell lung cancer (NSCLC) and melanoma (3 arms), sponsored by Novartis. Primary endpoints: Number of participants with Adverse Events up to 5 years, Dose limiting toxicities up to 3 years and 2 more. Started Feb 2017; status: terminated.
02
Drugs
naporafenib
03
Conditions
non-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT02974725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974725.